PYC Therapeutics advances blinding eye disease drug trials

Perth-based PYC Therapeutics (ASX:PYC) announced that its investigational drug candidate, PYC-001, has received a green light from the Safety Review Committee to progress to multiple-dose testing.

The decision follows an evaluation of safety and tolerability data from the Phase 1 single ascending dose study, specifically involving patients treated with a 60-microgram dose.

Autosomal dominant optic atrophy is a debilitating genetic condition that leads to progressive vision loss and eventual blindness.

Affecting approximately 1 in 35,000 individuals globally, the disease currently has no approved treatment options, leaving a clinical void that PYC-001 aims to fill by addressing the underlying genetic cause.

Following the SRC’s approval, the company will now integrate the 60-microgram dose into its ongoing Phase 1/2 multiple ascending dose study.

The stage will evaluate the safety and efficacy of repeat dosing, joining existing 10 and 30-microgram cohorts already under investigation.

At the time of reporting, PYC Therapeutics’ share price was $1.25.